Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG10 (Acoramidis) Phase 2 in Symptomatic ATTR-CM
NCT03458130Phase 2Completed
- Sponsor
- BridgeBio Pharma
- Start
- Apr 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) (3 arms), sponsored by BridgeBio Pharma. Primary endpoints: Change in Diastolic Blood Pressure at Day 28, Change in Heart Rate at Day 28 and 3 more. Started Apr 2018; status: completed.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT03458130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458130.